Hemostasis in neonates and children: Pitfalls and dilemmas

Blood Reviews

Volumn 24, Issue 2, 2010, Pages 63-68

  Monagle, Paul ^a   Ignjatovic, Vera ^b   Savoia, Helen ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Child; Development; Hemostasis; Neonate

Indexed keywords

ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR; HEPARIN; PLACEBO;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CHILD; CHILD CARE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL; DEVELOPMENTAL STAGE; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; GENOTYPE PHENOTYPE CORRELATION; GROWTH REGULATION; HEMOSTASIS; HUMAN; INTERVENTION STUDY; LABORATORY TEST; LUNG DISEASE; NEOPLASM; NEWBORN; NEWBORN APNEA; NEWBORN ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PHYSIOLOGICAL PROCESS; PREDICTION; PRIORITY JOURNAL; REFERENCE VALUE;

AGING; BLOOD COAGULATION; CHILD; CHILD, PRESCHOOL; HEMATOLOGIC DISEASES; HEMOSTASIS; HUMANS; INFANT, NEWBORN;

EID: 77249125778     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.12.001     Document Type: Article

References (38)

1. Andrew M., Paes B., Milner R., et al. Development of the human coagulation system in the healthy premature infant. Blood 72 (1988) 1651-1657
2. Andrew M., Paes B., Milner R., et al. Development of the human coagulation system in the full-term infant. Blood 70 (1987) 165-172
3. Andrew M., Vegh P., Johnston M., Bowker J., Ofosu F., and Mitchell L. Maturation of the hemostatic system during childhood. Blood 80 (1992) 1998-2005
4. Andrew M., Paes B., and Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 12 (1990) 95-104
5. Monagle P., Barnes C., Ignjatovic V., et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 95 (2006) 362-372
6. Chan K.L., Summerhayes R.G., Ignjatovic V., Horton S.B., and Monagle P.T. Reference values for kaolin-activated thromboelastography in healthy children. Anesth Analg 105 (2007) 1610-1613 [table of contents]
7. Monagle P., and Hagstrom J. Developmental haemostasis. In: Polin (Ed). Fetal and neonatal physiology. 3rd ed. (2003), St. Louis, Elsevier 1435-1447
8. Witt I., and Muller H. Phosphorus and hexose content of human foetal fibrinogen. Biochim Biophys Acta 221 (1970) 402-404
9. Hamulyak K., Nieuwenhuizen W., Devilee P.P., and Hemker H.C. Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns. Thromb Res 32 (1983) 301-310
10. Witt I., Muller H., and Kunzer W. Evidence for the existence of foetal fibrinogen. Thromb Diath Haemorrh 22 (1969) 101-109
11. Miller B.E., Tosone S.R., Guzzetta N.A., Miller J.L.K.K., and Brosius K.K. Fibrinogen in children undergoing cardiac surgery: is it effective?. Anesth Analg 99 (2004) 1341-1346
12. Martinez J., MacDonald K.A., and Palascak J.E. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 61 (1983) 1196-1202
13. Dang C.V., Shin C.K., Bell W.R., Nagaswami C., and Weisel J.W. Fibrinogen sialic acid residues are low affinity calcium binding sites that influence fibrin assembly. J Biol Chem 264 (1989) 15104-15108
14. Al Dieri R., Peyvandi F., Santagostino E., et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Throm Haemost 88 (2002) 576-582
15. Hemker H.C., and Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 74 (1995) 134-138
16. Hemker H.C., Giesen P., Al Dieri R., Regnault V., de Smedt E., and Wagenvoord R. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 (2003) 4-15
17. Hemker H.C., Wielders S., Kessels H., and Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 70 (1993) 617-624
18. Ignjatovic V., Greenway A., Summerhayes R., and Monagle P. Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis. Br J Haematol 138 (2007) 366-368
19. Wells P.S., Anderson D.R., Rodger M., et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 135 (2001) 98-107
20. Biss T.T., Brandao L.R., Kahr W.H., Chan A.K., and Williams S. Clinical probability score and D-dimer estimation lack utility in the diagnosis of childhood pulmonary embolism. J Thromb Haemost 7 (2009) 1633-1638
21. Bauman M.E., Belletrutti M.J., Bajzar L., et al. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels. Thromb Haemost 101 (2009) 86-92
22. Dix D., Andrew M., Marzinotto V., et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 136 (2000) 439-445
23. Kuhle S., Massicotte P., Dinyari M., et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 94 (2005) 1164-1171
24. Massicotte P., Adams M., Marzinotto V., Brooker L.A., and Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 128 (1996) 313-318
25. Massicotte P., Julian J.A., Gent M., et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 109 (2003) 101-108
26. Ignjatovic V., Furmedge J., Newall F., et al. Age-related differences in heparin response. Thromb Res 118 (2006) 741-745
27. Andrew M., Mitchell L., Vegh P., and Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 72 (1994) 836-842
28. Basu D., Gallus A., Hirsh J., and Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287 (1972) 324-327
29. Hull R.D., Raskob G.E., Hirsh J., et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315 (1986) 1109-1114
30. Ignjatovic V., Summerhayes R., Than J., Gan A., and Monagle P. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost 4 (2006) 2280-2282
31. Newall F., Ignjatovic V., Summerhayes R., et al. In vivo age dependency of unfractionated heparin in infants and children. Thromb Res 123 (2009) 710-714
32. Ignjatovic V., Summerhayes R., Gan A., et al. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate?. Thromb Res 120 (2007) 347-351
33. Schedin-Weiss S., Richard B., Hjelm R., and Olson S.T. Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence. Biochemistry 47 (2008) 13610-13619
34. Akl E.A., van Doormaal F.F., Barba M., et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev (2007) CD006652
35. Adcock D.M., Fink L.M., Marlar R.A., Cavallo F., and Zangari M. The hemostatic system and malignancy. Clin Lymph Myeloma 8 (2008) 230-236
36. Wojtukiewicz M.Z., Sierko E., and Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 30 (2004) 5-20
37. Niessen R.W., Lamping R.J., Peters M., Lamers W.H., and Sturk A. Fetal and neonatal development of antithrombin III plasma activity and liver messenger RNA levels in sheep. Pediatr Res 39 (1996) 685-691
38. Schmidt B., Gillie P., Mitchell L., Andrew M., Caco C., and Roberts R. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 158 (1998) 470-476